These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 29449411)

  • 41. Non-invasive imaging in experimental medicine for drug development.
    Matthews PM; Rabiner I; Gunn R
    Curr Opin Pharmacol; 2011 Oct; 11(5):501-7. PubMed ID: 21570913
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions.
    Figtree GA; Broadfoot K; Casadei B; Califf R; Crea F; Drummond GR; Freedman JE; Guzik TJ; Harrison D; Hausenloy DJ; Hill JA; Januzzi JL; Kingwell BA; Lam CSP; MacRae CA; Misselwitz F; Miura T; Ritchie RH; Tomaszewski M; Wu JC; Xiao J; Zannad F
    Circulation; 2021 Jul; 144(2):159-169. PubMed ID: 33876947
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Accelerating safe drug development: an ideal approach to approval.
    Grever MR
    Hematology Am Soc Hematol Educ Program; 2013; 2013():24-9. PubMed ID: 24319158
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacogenomics to Revive Drug Development in Cardiovascular Disease.
    Dubé MP; de Denus S; Tardif JC
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):59-64. PubMed ID: 26768480
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oncology drug discovery: planning a turnaround.
    Toniatti C; Jones P; Graham H; Pagliara B; Draetta G
    Cancer Discov; 2014 Apr; 4(4):397-404. PubMed ID: 24706659
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gadofosveset: MS 325, MS 32520, Vasovist, ZK 236018.
    Drugs R D; 2004; 5(6):339-42. PubMed ID: 15563237
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Development of ADCs Using Molecular Imaging].
    Yasunaga M; Manabe S; Tsuji A; Furuta M; Ogata K; Koga Y; Fujiwara Y; Saga T; Matsumura Y
    Yakugaku Zasshi; 2017; 137(5):535-544. PubMed ID: 28458285
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Label-free MS imaging from drug discovery to preclinical development.
    Hochart G; Hamm G; Stauber J
    Bioanalysis; 2014 Oct; 6(20):2775-88. PubMed ID: 25413708
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The year in molecular imaging.
    Osborn EA; Jaffer FA
    JACC Cardiovasc Imaging; 2010 Nov; 3(11):1181-95. PubMed ID: 21071007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular calcification: artificial intelligence and big data accelerate mechanistic discovery.
    Rogers MA; Aikawa E
    Nat Rev Cardiol; 2019 May; 16(5):261-274. PubMed ID: 30531869
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular biomarkers and surrogate end points: key initiatives and clinical trial challenges.
    Heinonen TM; Aamer M; Marshall C; Black DM; Tardif JC
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):989-94. PubMed ID: 23030288
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Technologies supporting analytical cytology: clinical, research and drug discovery applications.
    Cecic IK; Li G; MacAulay C
    J Biophotonics; 2012 Apr; 5(4):313-26. PubMed ID: 22271675
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Noninvasive structural, functional, and molecular imaging in drug development.
    Rudin M
    Curr Opin Chem Biol; 2009 Jun; 13(3):360-71. PubMed ID: 19447067
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Zebrafish models of cardiovascular diseases and their applications in herbal medicine research.
    Seto SW; Kiat H; Lee SM; Bensoussan A; Sun YT; Hoi MP; Chang D
    Eur J Pharmacol; 2015 Dec; 768():77-86. PubMed ID: 26494630
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mass spectrometry for the evaluation of cardiovascular diseases based on proteomics and lipidomics.
    Thomas A; Lenglet S; Chaurand P; Deglon J; Mangin P; Mach F; Steffens S; Wolfender JL; Staub C
    Thromb Haemost; 2011 Jul; 106(1):20-33. PubMed ID: 21614412
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Landscape of Innovation for Cardiovascular Pharmaceuticals: From Basic Science to New Molecular Entities.
    Beierlein JM; McNamee LM; Walsh MJ; Kaitin KI; DiMasi JA; Ledley FD
    Clin Ther; 2017 Jul; 39(7):1409-1425.e20. PubMed ID: 28652015
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advancing novel molecular imaging agents from preclinical studies to first-in-humans phase I clinical trials in academia--a roadmap for overcoming perceived barriers.
    Reilly RM; Lam K; Chan C; Levine M
    Bioconjug Chem; 2015 Apr; 26(4):625-32. PubMed ID: 25781873
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overview of drug discovery and development.
    Ator MA; Mallamo JP; Williams M
    Curr Protoc Pharmacol; 2006 Dec; Chapter 9():Unit9.9. PubMed ID: 22294181
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The use of pharmacometrics to optimize biosimilar development.
    Dodds M; Chow V; Markus R; Pérez-Ruixo JJ; Shen D; Gibbs M
    J Pharm Sci; 2013 Nov; 102(11):3908-14. PubMed ID: 24027111
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Frontiers in Live Bone Imaging Researches. Novel drug discovery by means of intravital bone imaging technology].
    Ishii M
    Clin Calcium; 2015 Jun; 25(6):907-13. PubMed ID: 26017869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.